NewAmsterdam Pharma Company N.V. announced the appointment of William H. Lewis, J.D., M.B.A., as Chair of its Board of Directors. Mr. Lewis has served as Chief Executive Officer of Insmed Incorporated since 2012, and as Chair of Insmed?s Board of Directors since 2018. Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of NewAmsterdam?s Board of Directors since inception.

Mr. Lewis has more than 30 years of executive experience in the pharmaceutical and finance industries both in the U.S. and internationally. Prior to joining Insmed in 2012, Mr. Lewis served as Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, which was acquired by Amryt in 2019. Prior to Aegerion, he spent more than 10 years working in investment banking in the U.S. and Europe.

He also previously worked for the U.S. government. Mr. Lewis holds a J.D. with Honors and an M.B.A., both from Case Western Reserve University, and a B.A., cum laude, from Oberlin College. He is a member of the Board of Trustees of Case Western Reserve University and of BioNJ.